Keith A. Reynolds

Moderna‘s vaccine showed 94.1 percent efficacy in patients 16 and older.

A regulatory panel has given the vaccine approval leaving only the official EUA approval before distribution.

After a review of phase three applications, the department will release $4.5 billion more than initially anticipated.

A survey has found an increase in the share of the general public willing to receive a COVID-19 vaccine.

The organization supports recommendations for the Pfizer BioNTech vaccine.

The vaccine is expected to be authorized for emergency use later this week.

The changes are intended to remove barriers to coordinated care and reduce regulatory burden.

While there are myriad apps available in digital storefronts hosted by Apple, Google and Amazon, it can be difficult to choose an effective app that also keeps patient health data safe.

The authorization came late Friday night.

The Vaccines and Related Biological Products Advisory Committee approved the vaccine, BNT162b2, paving the way to emergency use authorization.

The proposed rule would improve the electronic exchange of healthcare data and streamline processes to reduce administrative burden.

The report came out as the U.K. has started vaccinating patients.

Murthy previously held the post during the tail end of the Obama administration and the beginning of the Trump administration.

The chief of Infectious Disease at Massachusetts General Hospital would take the reins at a pivotal moment for the CDC.

The president-elect’s choice has already drawn pushback due to his defense of the ACA and abortion.

CMS says the new model will see physicians taking responsibility for their patients’ health outcomes.

As National Influenza Vaccination Week approaches, it’s time for all adults to get a flu shot.

Primary care spending has been trending down steadily for years.

The UK leapfrogged the rest of the western world in accepting the candidate which is shown to be about 95 percent effective against COVID-19.

This is the third year in a row that saw more insurers enter the marketplaces giving patients more options.

The organization is recommending a framework to ensure ethical allocations of much-needed vaccines during the pandemic.

The candidate showed 94.1 percent efficacy against COVID-19 and 100 percent against severe COVID-19.

The groups are urging Congress to ensure that changes scheduled to go into effect Jan. 1 are implemented.

This the first attempt to significantly modernize and clarify regulations around the self-referral law since it was enacted in 1989.

This free webinar will be held at 6 p.m. ET on Dec. 1.

The company tested two different dosing regimens with one shown to be more effective.

The candidate BNT162b2 was shown to be 95 percent effective against COVID-19.

While 60 percent of respondents reported an increase of COVID-19 cases, their level of strain remained mostly static.

This is the first approved COVID-19 diagnostic test that can be completed at home.

The policies touch on a number of topics including social determinants of health, high deductible health plans, and uninsured patients.